J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating

摩根大通维持爱美医疗(FOLD.US)买入评级

moomoo资讯 · 2024/11/08 21:32 · 评级/大行评级

J.P. Morgan analyst Anupam Rama maintains $Amicus Therapeutics (FOLD.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 48.2% and a total average return of 4.0% over the past year.

AnalystRecentRatingAutoNews_205926_20241108_02d70869fa675771437d36e0f966f9d569d0e923_1731141015918420_mm_en

Furthermore, according to the comprehensive report, the opinions of $Amicus Therapeutics (FOLD.US)$'s main analysts recently are as follows:

Amicus' third quarter revenues exceeded Street forecasts, boasting $120.4M from Galafold sales and $21.1M from purchase order sales. Post-results, adjustments were made to the financial model for the quarter, along with an update to the guidance and a shift of the discount year to 2025. Additionally, the cost of goods sold was revised upwards, reflecting management's commentary on inventory expenses for P+O.
Following the report of third-quarter sales surpassing consensus expectations and the company's subsequent increase in fiscal year guidance for Galafold and Pombiliti, the view is that Amicus' narrative may prove to be highly attractive to potential strategic acquirers in 2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根大通分析师Anupam Rama维持$爱美医疗 (FOLD.US)$买入评级。

根据TipRanks数据显示，该分析师近一年总胜率为48.2%，总平均回报率为4.0%。

AnalystRecentRatingAutoNews_205926_20241108_02d70869fa675771437d36e0f966f9d569d0e923_1731141015918420_mm_sc

此外，综合报道，$爱美医疗 (FOLD.US)$近期主要分析师观点如下：

Amicus第三季度的收入超过了华尔街的预期，其中Galafold的销售额为1.204亿美元，采购订单销售额为2,110万美元。公布业绩后，对本季度的财务模型进行了调整，并更新了指导方针，并将折扣年份移至2025年。此外，商品销售成本向上修正，反映了管理层对P+O库存支出的评论。
继第三季度销售额超过市场普遍预期的报告以及该公司随后提高了对加拉福德和庞比利蒂的财年预期之后，人们认为Amicus的说法可能会在2025年对潜在的战略收购方产生极大的吸引力。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating

J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating

风险及免责提示

声明